Short answer
STANDARD BIOTOOLS INC. (LAB) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $21M (down 48.2% year over year) with net income of $127M.
Q1 2026 key financials · XBRL
- Revenue
- $21M
- −48.2% YoY
- Net income
- $127M
- +588.1% YoY
- Operating margin
- -59.1%
- Gross margin
- 53.5%
- EPS (diluted)
- $0.33
- +571.4% YoY
Source: XBRL data from the STANDARD BIOTOOLS INC. (LAB) Q1 2026 10-Q on SEC EDGAR. USD.
STANDARD BIOTOOLS INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $21.1M, up 5% YoY from $20.2M, driven by consumables
- Consumables $11.0M, up 35%; instruments $4.5M, down 33%, weakest product line
- Gross margin 53.5% vs 54.6%; operating loss margin (59)% vs (133)% YoY
- Cash, equivalents and investments $526.5M vs $213.3M; operating cash use $46.6M vs $30.3M
- SomaScan sale generated $363.2M cash; macro pressures, budget limits and constrained funding delayed instrument purchases
Risk Factors
- New listing risk triggered by Nasdaq’s April 20, 2026 notice after 30 consecutive sub-$1.00 closing bids
- Most material update: delisting deadline of October 19, 2026, with potential liquidity and capital-raising damage
- Regulatory compliance risk: failure to regain $1.00 bid compliance for 10 consecutive business days
- Market risk: delisting could impair the ability to complete a strategic transaction
- Financial risk: $40.5 million spent repurchasing 15,448,533 shares under the $50.0 million program
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other STANDARD BIOTOOLS INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.